Brief: Invion Says Orphan Drug Designation Granted By U.S. FDA For Anal Cancer
20/08/2025 02:27
Aug 20 (Reuters) - Invion Ltd IVX.AX: ORPHAN DRUG DESIGNATION GRANTED BY U.S. FDA FOR ANAL CANCER Further company coverage: IVX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invion
See all newsAustralia's Invion rises after securing clinical trial funding arrangements
Brief: Invion Ltd Says Funding Agreements Cover Up To 85% Of Clinical Trials Costs
Brief: Invion Announces Preclinical Research Collaboration With Percheron Therapeutics
Australia's Invion enters ophthalmology agreement with Sangmyung Innovation
Brief: Invion Signs First Ophthalmology Collaboration Agreement With Sangmyung Innovation